Format

Send to

Choose Destination
Leuk Lymphoma. 2009 Jun;50(6):886-91. doi: 10.1080/10428190902943077.

Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab.

Author information

1
Micromet AG, Germany. dirk.nagorsen@micromet.de

Abstract

Hematologic malignancies are predominantly treated with chemotherapy or a combination of chemotherapy with monoclonal antibodies. Current treatment regimens often are not satisfactory due to severe side effects and a substantial proportion of relapsed patients. This has prompted the development of better tolerated and more efficacious immunotherapeutic strategies for the treatment of lymphoma and leukemia. With blinatumomab (MT103) a first antibody, which can potentially engage all cytotoxic T cells of a patient for tumor cell lysis, is now available for clinical evaluation. Blinatumomab is a single-chain bispecific antibody construct with specificity for CD19 and CD3 belonging to the class of bispecific T cell engager. Here, we review the current progress in development of blinatumomab for treatment of patients with CD19-expressing hematological malignancies.

PMID:
19455460
DOI:
10.1080/10428190902943077
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center